Very Rare: Excess daytime somnolence and sudden sleep onsetUncommon: Confusion, psychomotor agitation, hallucinations Rare: Diarrhoea, abdominal pain, retroperitoneal fibrosis, gastrointestinal ulcer, gastrointestinal haemorrhageUncommon: Hypotension including orthostatic hypotension (which may in very rare instances lead to collapse) Very Rare: Reversible pallor of fingers and toes induced by cold (especially in patients who have a history of Raynaud's phenomenon)Very rare: Cardiac valvulopathy (including regurgitation) and related disorders (pericarditis and pericardial effusion). Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Consider dosage reduction or discontinuation of therapy if symptoms occur.• Hallucinations: Visual or auditory hallucinations may occur when administered alone or concomitantly with levodopa; dose reductions or discontinuation may be necessary. Take a missed dose as soon as you think about it. Neuroleptic malignant syndrome (NMS) is a potentially fatal syndrome which is rarely seen during treatment with antipsychotic medications. No dose adjustment recommended. Adverse reactions are ranked under heading of frequency, the most frequent first, using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) including isolated reports. Dosage may then be increased by 2.5mg at 2 to 3 day intervals as follows: - 2.5mg eight-hourly, 2.5mg six-hourly, 5mg six-hourly.Introduce BROMOCRIPTINE gradually, as follows: Week 1: 1mg to 1.25mg at bed time. The areas of application of BROMOCRIPTINE are divided into endocrinological and neurological indications. However, the majority of women discontinued use within 8 weeks of pregnancy.Bromocriptine should be discontinued if pregnancy is confirmed unless needed for treatment of a rapidly expanding macroadenoma. Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Headache (12.5%) 1.4. This is in order to avoid suppression of prolactin to below normal levels, with consequent impairment of luteal function.Gynaecological assessment, preferably including cervical and endometrial cytology, is recommended for women receiving BROMOCRIPTINE for extensive periods. Clipboard, Search History, and several other advanced features are temporarily unavailable. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. dose as tolerated; Max: 20 mg PO qid; Info: continue x7-10 days, then taper dose over 3 days to D/C (see section 4.4 'Special warnings and precautions for use').